Exocrine Pancreatic Insufficiency (EPI) Market New Product Development & Latest Trends

Introduction
Exocrine Pancreatic Insufficiency (EPI) is a chronic digestive condition where the pancreas fails to produce enough enzymes to properly digest food. This leads to symptoms such as steatorrhea (fatty stools), weight loss, bloating, abdominal pain, and nutritional deficiencies. EPI is most often caused by chronic pancreatitis, cystic fibrosis, pancreatic cancer, and gastrointestinal surgery, with a growing patient pool due to the global rise in gastrointestinal and metabolic disorders.

The mainstay of treatment is Pancreatic Enzyme Replacement Therapy (PERT), alongside dietary modifications and supportive care. Increasing disease awareness, earlier diagnosis, and new PERT formulations are fueling market expansion.
In 2024, the global Exocrine Pancreatic Insufficiency Market is valued at USD 4.2 billion and is projected to reach USD 8.3 billion by 2034, growing at a CAGR of 7.1% during 2025-2034.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71112

Market Overview
• Market Size 2024: USD 4.2 billion
• Forecast 2034: USD 8.3 billion
• CAGR (2025-2034): 7.1%
• Key Drivers: Rising prevalence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer; growing adoption of PERT; and increasing physician awareness.
• Key Challenges: High cost of long-term enzyme therapy, underdiagnosis in developing regions, and limited awareness among primary care providers.
• Leading Players: AbbVie, Viatris, Nordmark Arzneimittel, Allergan, Janssen Pharmaceuticals, Chiesi Farmaceutici, Cipla, Dr. Reddy's Laboratories, Sun Pharma, Alcresta Therapeutics.

The market remains enzyme therapy-driven, but innovations in diagnostics and patient monitoring are opening new opportunities.

Segmentation Analysis
By Product
• Pancreatic Enzyme Replacement Therapy (PERT) formulations (lipase, amylase, protease combinations)
• Nutritional supplements
• Diagnostics (imaging, stool elastase test kits)
• Supportive care products

By Therapy
• Pharmacological therapy (PERT)
• Nutritional therapy
• Combination therapy
• Experimental therapies

By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Specialty clinics
• Online pharmacies

By End-Use
• Hospitals
• Gastroenterology clinics
• Research institutes
• Homecare

By Application
• Chronic pancreatitis-induced EPI
• Cystic fibrosis-related EPI
• Pancreatic cancer-related EPI
• Post-surgical EPI
• Other gastrointestinal disorders

Summary of Segmentation
The PERT segment dominates, accounting for the majority of market revenue, while diagnostic kits and online pharmacies are expected to grow at the fastest pace due to increasing demand for early detection and convenient therapy access.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71112/exocrine-pancreatic-insufficiency-market

Regional Analysis
• North America: Largest market share, supported by advanced diagnostics, strong adoption of PERT, and high awareness among gastroenterologists.
• Europe: Strong growth driven by cystic fibrosis programs, reimbursement policies, and expansion of PERT formulations.
• Asia-Pacific: Fastest-growing region (CAGR >8%), driven by rising prevalence of chronic pancreatitis and pancreatic cancer, healthcare modernization, and growing awareness.
• Middle East & Africa: Moderate growth due to limited diagnosis and affordability issues, though rare disease programs are improving access.
• Latin America: Brazil and Mexico lead growth, supported by healthcare improvements and better diagnostic capabilities.

Regional Trends Summary
While North America and Europe dominate today, Asia-Pacific is emerging as the fastest-growing region, owing to its large patient base and rising healthcare investments.

Market Dynamics
Key Growth Drivers
• Rising prevalence of chronic pancreatitis, pancreatic cancer, and cystic fibrosis.
• Expanding use of PERT formulations as the gold standard of care.
• Increasing global awareness and earlier diagnosis.
• Growing use of nutritional supplements and digital monitoring tools.

Key Challenges
• Underdiagnosis due to non-specific symptoms.
• High cost of lifelong PERT for patients in low-income countries.
• Limited availability of specialized gastroenterology care in rural regions.
• Dependence on lifelong treatment without curative solutions.

Latest Trends
• Development of next-generation PERT formulations with improved stability and dosing.
• Expansion of point-of-care diagnostic tools such as stool elastase kits.
• Integration of digital health and telemedicine for EPI management.
• Clinical research into microbiome-modulating therapies as adjuncts to PERT.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71112

Competitive Landscape
Major Players
• AbbVie
• Viatris
• Nordmark Arzneimittel
• Allergan
• Janssen Pharmaceuticals
• Chiesi Farmaceutici
• Cipla
• Dr. Reddy's Laboratories
• Sun Pharma
• Alcresta Therapeutics

Competitive Insights
The EPI market is moderately consolidated, with AbbVie leading through its Creon (PERT) brand. Viatris and Nordmark also have strong market shares in enzyme formulations. Emerging biotech firms like Alcresta Therapeutics are focusing on innovative delivery methods and adjunct therapies. Strategic collaborations, licensing deals, and expanded regional distribution remain central to competition.

Conclusion
The global Exocrine Pancreatic Insufficiency Market is on a strong upward trajectory. From USD 4.2 billion in 2024 to USD 8.3 billion by 2034, the market will grow at a CAGR of 7.1%, fueled by the adoption of enzyme therapy, increasing prevalence of pancreatic disorders, and advances in diagnostics.
• Opportunities: Asia-Pacific growth, next-generation enzyme formulations, and digital patient management.
• Challenges: Underdiagnosis, affordability barriers, and lack of curative therapies.
• Key Takeaway: Companies that focus on innovative PERT formulations, affordable therapy models, and global screening programs will lead the EPI market in the next decade.

This report is also available in the following languages : Japanese (外分泌膵機能不全市場), Korean (외분비 췌장 부전 시장), Chinese (胰腺外分泌功能不全市场), French (Marché de l'insuffisance pancréatique exocrine), German (Markt für exokrine Pankreasinsuffizienz), and Italian (Mercato dell'insufficienza pancreatica esocrina), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71112

Our More Reports:

Short Bowel Syndrome Market
https://exactitudeconsultancy.com/reports/71128/short-bowel-syndrome-market

Autoimmune Gastritis Market
https://exactitudeconsultancy.com/reports/71130/autoimmune-gastritis-market

Chronic Idiopathic Constipation Market
https://exactitudeconsultancy.com/reports/71132/chronic-idiopathic-constipation-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.